8,177 reports of this reaction
3.3% of all CARVEDILOL reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for CARVEDILOL, manufactured by Waylis Therapeutics LLC. There are 8,177 FDA adverse event reports linking CARVEDILOL to DYSPNOEA. This represents approximately 3.3% of all 250,588 adverse event reports for this drug.
Patients taking CARVEDILOL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among CARVEDILOL users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for CARVEDILOL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 8,177 FDA reports for CARVEDILOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.3% of all adverse event reports for CARVEDILOL, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking CARVEDILOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.